|
1
|
Schiffman M and Castle PE: The promise of
global cervical cancer prevention. N Engl J Med. 353:2101–2104.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Mandelblatt JS, Lawrence WF, Womack SM,
Jacobson D, Yi B, Hwang YT, Gold K, Barter J and Shah K: Benefts
and costs of using HPV testing to screen for cervical cancer. JAMA.
287:2372–2381. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Small W Jr, Mell LK, Anderson P, et al:
Consensus guidelines for delineation of clinical target volume for
intensity-modulated pelvic radiotherapy in postoperative treatment
of endometrial and cervical cancer. Int J Radiat Oncol Biol Phys.
71:428–434. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Grigsby PW: Radiotherapy for pelvic
recurrence after radical hysterectomy for cervical cancer. Radiat
Med. 23:327–330. 2005.PubMed/NCBI
|
|
5
|
Klopp AH and Eifel PJ: Chemoradiotherapy
for cervical cancer in 2010. Curr Oncol Rep. 13:77–85. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Tanderup K, Georg D, Pötter R, Kirisits C,
Grau C and Lindegaard JC: Adaptive management of cervical cancer
radiotherapy. Semin Radiat Oncol. 20:121–129. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Bromley SK, Mempel TR and Luster AD:
Orchestrating the orchestrators: Chemokines in control of T cell
traffic. Nat Immunol. 9:970–980. 2008. View
Article : Google Scholar : PubMed/NCBI
|
|
8
|
Luster AD, Unkeless JC and Ravetch JV:
Gamma-interferon transcriptionally regulates an early-response gene
containing homology to platelet proteins. Nature. 315:672–676.
1985. View
Article : Google Scholar : PubMed/NCBI
|
|
9
|
Campanella GS, Colvin RA and Luster AD:
CXCL10 can inhibit endothelial cell proliferation independently of
CXCR3. PLoS One. 5:e127002010. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Arenberg DA, Kunkel SL, Polverini PJ,
Morris SB, et al: Interferon-gamma-inducible protein 10 (IP-10) is
an angiostatic factor that inhibits human non-small cell lung
cancer (NSCLC) tumorigenesis and spontaneous metastases. J Exp Med.
184:981–992. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Pertl U, Luster AD, Varki NM, Homann D,
Gaedicke G, Reisfeld RA and Lode HN: IFN-gamma-inducible protein-10
is essential for the generation of a protective tumor-specific CD8
T cell response induced by single-chain IL-12 gene therapy. J
Immunol. 166:6944–6951. 2001. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Feldman AL, Friedl J, Lans TE, et al:
Retroviral gene transfer of interferon-inducible protein 10
inhibits growth of human melanoma xenografts. Int J Cancer.
99:149–159. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yang LL, Chen P, Luo S, Li J, Liu K, Hu HZ
and Wei YQ: CXC-chemokine-ligand-10 gene therapy efficiently
inhibits the growth of cervical carcinoma on the basis of its
anti-angiogenic and antiviral activity. Biotechnol Appl Biochem.
53:209–216. 2009.PubMed/NCBI
|
|
14
|
Yang LL, Wang BQ, Chen LL, Luo HQ and Wu
JB: CXCL10 enhances radiotherapy effects in HeLa cells through cell
cycle redistribution. Onclogy Lett. 3:383–386. 2012.
|
|
15
|
Xiao F, Wei Y, Yang L, et al: A gene
therapy for cancer based on the angiogenesis inhibitor, vasostatin.
Gene Ther. 9:1207–1213. 2002. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Somasundaram K and El-Deiry WS: Inhibition
of p53-mediated transactivation and cell cycle arrest by E1A
through its p300/CBP-interacting region. Oncogene. 14:1047–57.
1997. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Li G, Tian L, Hou JM, et al: Improved
therapeutic effectiveness by combining recombinant CXC chemokine
ligand 10 with cisplatin in solid tumors. Clin Cancer Res.
11:4217–4224. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Han GD, Suzuki K, Koike H, et al:
IFN-inducible protein-10 plays a pivotal role in maintaining
slit-diaphragm function by regulating podocyte cell-cycle balance.
J Am Soc Nephrol. 17:442–453. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Mazumder S, Plesca D and Almasan A: A
jekyll and hyde role of cyclin E in the genotoxic stress response:
switching from cell cycle control to apoptosis regulation. Cell
Cycle. 6:1437–1442. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Kawauchi S, Yamamoto Y, Uchida K, Chochi
Y, Kondo T, Oga A and Sasaki K: Signifcance of cyclin E and p27
expression in malignant ovarian germ cell tumors: Correlation with
the cell proliferation activity and clinicopathologic features.
Oncol Rep. 16:1029–1033. 2006.PubMed/NCBI
|
|
21
|
Frosina G: DNA repair and resistance of
gliomas to chemotherapy and radiotherapy. Mol Cancer Res.
7:989–999. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Pawlik TM and Keyomarsi K: Role of cell
cycle in mediating sensitivity to radiotherapy. Int J Radiat Oncol
Biol Phys. 59:928–942. 2004. View Article : Google Scholar : PubMed/NCBI
|
